» R&D-based and product-driven pharmaceutical company
Innovative R&D at low cost and high efficiency
» First in class and best in class products with worldwide IP protection
» Low FTW cost
» Targeting 3.5 years from discovery to US IND
» US IND trials up to proof-of-concept
» China IND trials for 'First Class New Drug' registration, fast market entry and price protection
Growth driven by global view and strategy
» Established 50,000 sq. ft. state-of-the-art R&D center in Taiwan in 2/2002 with 91 staff in total
» Parallel in-license and internal discovery for Asian and ROW markets
» Conducted four trials under US IND authority, including multi-national trial sites
» Subsidiary in Beijing for clinical trials and registration under Chinese IND authority on two occassions
» Established a platform for US/EU companies to develop and market products in China
» Risk and reward sharing: Fujisawa, P&G Pharmaceuticals, plus other partners under discussion
» TaiGen partnership opportunities
Out-licensing opportunity in late-stage projects
» Nemonoxacin for US / EU / Japan markets
Co-development / Out-licensing opportunities in early-stage projects
» TG-0054, stem and progenitor cell mobilizer
» HCV program
In-licensing opportunities in Asian development rights
» Asian prevalent diseases
» Comprehensive IP protection
Research alliance
» Risk and reward sharing
» From lead discovery / optimization to proof-of-concept clinical trials
Please contact
John Jin, Vice President for Global Business Development
TaiGen Biotechnology Co., Ltd.
7F, 138 Shin Ming Rd., Neihu Dist., Taipei, Taiwan 114, R.O.C.
Tel. 886-2-2790-1861, ext. 1710 (Taipei Office)
Fax. 886-2-2796-3606 (Taipei Office)
johnjin@taigenbiotech.com
Top
